BC Week In Review | Jun 9, 2017
Clinical News

Endocyte stops enrollment in Phase Ia/Ib solid tumor trial of EC1456

Endocyte Inc. (NASDAQ:ECYT) will stop enrollment in the Phase Ib portion of an open-label, U.S. Phase Ia/Ib trial of twice-weekly 6 mg/m 2 EC1456 in up to 40 folate receptor-positive non-small cell lung cancer (NSCLC)...
BC Week In Review | Jun 9, 2017
Clinical News

Endocyte narrows Phase I development program for CRPC candidate EC1169

Endocyte Inc. (NASDAQ:ECYT) will narrow its development program for EC1169 to focus on the cohort of up to 50 taxane-exposed, metastatic castration-resistant prostate cancer (CRPC) patients in a Phase Ib trial. The company will stop...
BC Week In Review | Mar 9, 2015
Clinical News

EC1169: Phase I data

Data from 7 evaluable patients with recurrent mCRPC in an open-label, U.S. Phase I trial showed that once-weekly 0.3, 0.45 and 0.6 mg/m 2 and thrice-weekly 0.2, 0.3, 0.45 and 0.6 mg/m 2 doses of...
Items per page:
1 - 3 of 3